TFFP - רווח נקי למניה (EPS TTM) TFF Pharmaceuticals Inc.

The pharmaceutical sector is facing the liquidation of TFF Pharmaceuticals (TFFP), whose assets are currently being sold off. The firm previously developed unique inhalation powder delivery methods and minimized costs through research outsourcing. The current value of the rolling annual EPS demonstrates the earnings per share trend, where -6.44 indicates the current level, determining the business's final margin of safety before closure.

TFF Pharmaceuticals develops non-cyclical inhalation drug delivery technologies, the value of which is based on its patent portfolio. Net income per share (TTM) measures the final financial result distributed across the total volume of issuance for the year. This metric allows an investor to assess the real efficiency of business capitalization regardless of macroeconomic cycles. For this model, the indicator reflects the company's ability to transform partner budgets into shareholder value. Analyzing the dynamics of the rolling 12-month earnings per share helps identify hidden margin erosion.